|Day Low/High||2.95 / 3.16|
|52 Wk Low/High||0.98 / 3.37|
We added a name to the portfolio's Bullpen as a whirlwind quarter came to an end.
We exited 2 positions and took some profits during a busy week for the portfolio.
We initiated a new position and made several other trades during a week of twists and turns.
We initiated 2 new positions in a week dominated by political events.
Five Year Term Loan Agreement Provides Up To $35 Million
Investors in Antares Pharma Inc. saw new options begin trading this week, for the July 21st expiration.
It was a busy week of moves in the portfolio as we head into the latter half of the second quarter.
We initiated one new position and exited another last week, while several other names reported earnings.
BETR and ATRS report March-quarter numbers. Plus, post-call commentary on USA Technologies.
Multiple Drug Device Combination Products Pending FDA Approval
During a busy week of earnings and data, we exited 2 positions and initiated a small one.
We'll see what happens in the way of reaction to Trump's tax policy this afternoon, but if we sell off I'm likely going to be a buyer.
We exited one position and downgraded another as earnings season heated up.
We added a new name to the portfolio as the market took a breather in a shortened trading week.
We beat the benchmark Russell 2000 for the quarter, and we await a busy week on the economic front.
We are keeping an eye on rate-sensitive names for possible buying opportunities, as stocks fell around 1.5% this week.
Investors in Antares Pharma Inc. saw new options begin trading this week, for the November 17th expiration.
We picked up more Abraxas Petroleum on weakness, while the market rebounded slightly after the FOMC announced the anticipated quarter-point rate hike.
With the stock jumping on 4Q results, we'll lower our rating.